CHELMSFORD, Mass. — ZOLL said its Zenix professional monitor/defibrillator has received approval under the European Union’s Medical Device Regulation 2017/745, clearing the way for broader use of the device across European emergency medical services and hospital settings.
Zenix is the company’s most advanced monitor/defibrillator to date and was developed using extensive customer feedback from clinicians and EMS professionals. ZOLL said the device is designed to improve efficiency and clarity in high-pressure environments by combining an intuitive interface with advanced clinical functionality.
The system features a large, durable touchscreen that displays critical patient information when it is needed most. Clinicians can customize settings in real time, allowing them to adapt quickly during emergencies and maintain control in fast-moving situations. ZOLL said the design aims to reduce cognitive load and streamline workflows for both pre-hospital and in-hospital care teams.
Zenix is equipped with the company’s Real BVM Help and Real CPR Help technologies, which provide real-time clinical feedback to support high-quality ventilation and cardiopulmonary resuscitation. According to ZOLL, these tools help clinicians assess and adjust their actions during resuscitation efforts, supporting more consistent delivery of care.
“Whether you are a hospital clinician or an EMS professional, the ZOLL Zenix monitor/defibrillator is designed to work the way you work,” said Elijah White, President of ZOLL Acute Care Technology. “Zenix is our most advanced monitor/defibrillator, and yet it’s incredibly easy to use—virtually all functions of the device are accessible with three screen-touches or less. Along with the X Series, R Series and ZOLL M2, Zenix extends ZOLL’s leadership in professional monitors/defibrillators with unique features and intuitive design.”
ZOLL said the MDR approval reflects compliance with the EU’s updated regulatory framework, which emphasizes clinical evidence, safety, and post-market oversight for medical devices. The company said the clearance supports its plans to expand availability of Zenix across European healthcare systems while continuing to focus on usability and clinical performance.
